Study to Evaluate the Safety and Antitumor Activity of CX-2009 Monotherapy and in Combination With CX-072 in Advanced Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Neoplasms|Breast Neoplasms|Breast Neoplasms, Triple-Negative|Breast Cancer|Breast Neoplasms, Hormone Receptor Positive/HER2 Negative
Interventions: DRUG: CX-2009|DRUG: CX-072
Sponsor: CytomX Therapeutics